# US 12,214,026 B2 · Vaccine for falciparum malaria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,214,026 B2
- Document ID: US12214026B2
- Status: Granted
- Kind: B2
- Application number: 18/154,642
- Filed: 2023-01-13
- Published: 2023-09-21
- Granted: 2025-02-04
- Earliest claimed: 2011-12-02
- Assignees: Rhode Island Hospital; Seattle Children's Hospital
- Applicants: Rhode Island Hospital; Seattle Children's Hospital
- Inventors: Jonathan Kurtis; Christian Parcher Nixon; Dipak Kumar Raj; Jennifer Frances Friedman; Michal Fried; Patrick Emmet Duffy
- Web page: https://patentgrep.com/patent/US12214026B2

## CPC

- A61K 39/015: Hemosporidia antigens, e.g. Plasmodium antigens
- A61K 39/39575: {against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants}
- A61P 33/00: Antiparasitic agents
- C07K 14/445: Plasmodium
- C07K 16/205: {Plasmodium}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/575: {humoral response}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides compositions and methods for preventing or reducing the severity of malaria.

## Claims

### Claim 1

A method for reducing the severity of malaria or immunizing against malaria in a subject, comprising the step of administering a composition to the subject;
wherein the composition comprises a polypeptide selected from the group consisting of: CDPK5 (SEQ ID NO: 47), SERA5 (SEQ ID NOS: 70, 72), PfSUB1 (SEQ ID NO: 74), and PfPKG (SEQ ID NO: 76) or a combination of polypeptides thereof;
wherein the administration of the composition including the polypeptide or combination of polypeptides elicits an immune response to the polypeptide or combination of polypeptides;
wherein the immune response inhibits schizont egress from red blood cells;
thereby reducing the severity of malaria or immunizing against malaria in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the immune response is an antibody response.

### Claim 3 (depends on 1)

The method of claim 1, wherein the immune response is a cellular immune response.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition comprises the polypeptide PfSERA5.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition further comprises the polypeptide PfSEP-1A.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 7 (depends on 1)

The method of claim 1, wherein the subject is an adolescent female or a female of childbearing age.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition is administered intramuscularly.